Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O<sup>6</sup>-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS TrialUlrich Herrlinger, Martin Glas, Niklas Schäfer et al.|Journal of Clinical Oncology|2016Cited by 197
Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07)Dagmar Beier, Peter Hau, Martin Proescholdt et al.|Neuro-Oncology|2017Cited by 90
Non-Invasive Prediction of IDH Mutation in Patients with Glioma WHO II/III/IV Based on F-18-FET PET-Guided In Vivo 1H-Magnetic Resonance Spectroscopy and Machine LearningElisabeth Bumes, Markus Hutterer, Markus J. Riemenschneider et al.|Cancers|2020Cited by 45
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastomaNiklas Schäfer, Ulrich Herrlinger, Martin Proescholdt et al.|Neuro-Oncology|2017Cited by 21
Validation Study for Non-Invasive Prediction of IDH Mutation Status in Patients with Glioma Using In Vivo 1H-Magnetic Resonance Spectroscopy and Machine LearningElisabeth Bumes, Markus Hutterer, Claudia Fellner et al.|Cancers|2022Cited by 6